Table of Contents:

1 Report Prologue
2 Market Introduction
2.1 Scope of Study
2.2 Research Objective
2.3 Assumptions & Limitations
2.3.1 Assumptions
2.3.2 Limitations
3 Research Methodology
3.1 Primary Research Methodology
3.2 Secondary Research Methodology
3.3 Market Share Analysis
3.4 Trade Analysis
3.5 Market Pricing Approach
4 Market Dynamics
4.1 Introduction
4.2 Drivers
4.2.1 Rising Prevalence of Autism Disorder and Pervasive Developmental Disorder Have Fueled the Growth of the Market.(PDD)
4.2.2 Expected Approvals of Off-Label Drugs to Treat Autism Disorder Has Driven the Market Growth
4.2.3 Rising government or privately held societies taking initiatives to create the awareness about the disease
4.3 Restraints
4.3.1 Weak Product Pipeline of First Drugs for Autism
4.3.2 Unknown Etiology and Pathophysiology of the Disorder Prevent Effective Treatment Options
4.4 Opportunities
4.4.1 Rising Investments by Venture Non-Pharmacology Activities
4.5 Mega Trends
4.6 Macroeconomic Indicators
5 Market Factor Analysis
5.1 Porter's Five Forces Model
5.1.1 Bargaining Power of Suppliers
5.1.2 Bargaining Power of Buyers
5.1.3 Threat of New Entrants
5.1.4 Threat of Substitutes
5.1.5 Intensity of Rivalry
5.2 Value Chain Analysis
5.2.1 R&D
5.2.2 Manufacturing
5.2.3 Distribution & Sales
5.2.4 Post-Sales Monitoring
5.3 Pricing Analysis
5.4 Investment Opportunity Analysis
5.5 Demand & Supply: Gap Analysis
6 Global Autism Disorder & Treatment Market, By Type
6.1 Introduction
6.2 Asperger Syndrome
6.3 Pervasive Developmental Disorders (PDD)
7 Global Autism Disorder & Treatment Market, By Treatment Type
7.1 Introduction
7.2 Expert Opinion: Oxytocin
7.3 ABA (applied behavioral analysis)
7.4 Hyperbaric oxygen therapy
7.5 Chelation therapy
7.6 Oxytocin therapy
8 Global Autism Disorder & Treatment Market, By Drugs
8.1 Introduction
8.2 Selective Serotonin Reuptake Inhibitors (SSRIs)
8.3 Anti-convulsants
8.4 Stimulants
8.5 Anti-psychotic
9 Global Autism Disorder & Treatment Market, By Region
9.1 Introduction
9.2 Americas
9.3 North America
9.3.1 U.S.
9.4 Canada
9.4.1 South America
9.5 Europe
9.5.1 Germany
9.5.2 France
9.5.3 UK
9.5.4 Italy
9.5.5 Spain
9.5.6 Rest of Western Europe
9.5.7 Eastern Europe
9.6 Asia Pacific
9.6.1 Japan
9.6.2 China
9.6.3 India
9.6.4 Australia
9.6.5 Republic of Korea
9.6.6 Rest of Asia Pacific
9.7 Middle East & Africa
9.7.1 U.A.E.
9.7.2 Saudi Arabia
9.7.3 Oman
9.7.4 Kuwait
9.7.5 Qatar
9.7.6 Rest of the Middle East & Africa
10 Competitive Landscape
10.1 Company Market Share Analysis
10.1.1 Introduction
10.2 Competitive Landscape
10.2.1 Introduction
10.3 Recent Developments, 2013-2018
11 Company Profiles
11.1 Pfizer Inc.
11.1.1 Company Overview
11.1.2 Financials
11.1.3 Products
11.1.4 Strategy
11.1.5 Key Developments
11.2 Allergan, Plc
11.2.1 Company Overview
11.2.2 Financials
11.2.3 Products
11.2.4 Strategy
11.2.5 Key Developments
11.3 Eli Lilly and Company
11.3.1 Company Overview
11.3.2 Financials
11.3.3 Products
11.3.4 Strategy
11.3.5 Key Developments
11.4 Bristol-Myers Squibb Company
11.4.1 Company Overview
11.4.2 Financials
11.4.3 Products
11.4.4 Strategy
11.4.5 Key Developments
11.5 Sun Pharmaceutical Industries Ltd.
11.5.1 Company Overview
11.5.2 Financials
11.5.3 Products
11.5.4 Strategy
11.5.5 Key Developments
11.6 Johnson & Johnson Services, Inc.
11.6.1 Company Overview
11.6.2 Financials
11.6.3 Products
11.6.4 Strategy
11.6.5 Key Developments
11.7 Teva Pharmaceutical Industries Ltd.
11.7.1 Company Overview
11.7.2 Financials
11.7.3 Products
11.7.4 Strategy
11.7.5 Key Developments

11.8 Merck & Co. Inc
11.8.1 Company Overview
11.8.2 Financials
11.8.3 Products
11.8.4 Strategy
11.8.5 Key Developments
11.9 Novartis AG
11.9.1 Company Overview
11.9.2 Financials
11.9.3 Products
11.9.4 Strategy
11.9.5 Key Developments
11.1 Otsuka Holdings Co. Ltd
11.10.1 Company Overview
11.10.2 Financials
11.10.3 Products
11.10.4 Strategy
11.10.5 Key Developments
11.11 Consern Pharma Private Limited
12 Conclusion
12.1 Key Findings
12.1.1 CEO's Viewpoint
12.1.2 Key Companies to Watch
12.1.3 Prediction of Dietary Supplements in an Age of Personalized Nutrition Industry
13 Appendix
13.1 Discussion Blue Print
13.2 Expert Opinion: Oxytocin
13.3 References